UPC Analytics
DEEN
Übersicht · Eingereicht: 30. Apr. 2025

UPC_CoA_393/2025

EMBOLIC PROTECTION DEVICE

BerufungenHauptberufungCourt of AppealAppealCase Closed
Parteien

Kläger

  • Emboline, Inc.
Vertreter: Thure Schubert (Vossius & Partner Patentanwälte Rechtsanwälte mbB)

Beklagte

  • AorticLab srl
Vertreter: Sabine Agé (Hoyng ROKH Monegier)
Richter
  • Rian Kalden
  • Patricia Rombach
  • Ingeborg Simonsson
Patente
  • EP 2 129 425
CPC-Codes: A61F2230/0065, A61F2230/0006, A61F2250/0023, A61F2250/0003, A61F2/0105, A61F2002/018, A61F2250/0069, A61F2230/0067, A61F2230/0069, A61F2/011

Sektor: Pharmaceutical & Medical

Ausgang
Abgewiesen
Eingereicht: 30. Apr. 2025
Erste Entscheidung:
Sprache: English

The Court of Appeal allowed AorticLab's appeal and set aside the Munich Local Division's order granting Emboline's application for security for costs. The CoA held that Art. 69(4) UPCA provides no legal basis for a security for costs at the request of the claimant in an infringement action in response to a defendant's counterclaim for revocation. Allowing such security would unreasonably restrict the defendant's right to raise an invalidity defence by means of a mandatory counterclaim.

Im UPC-Register öffnen